Case Study:
Earlier Patient Diagnosis – Complex Illness
Earlier Patient Diagnosis – Complex Illness
This client discovered that due to the complex nature of the condition, primary care physicians were not diagnosing patients and sending them to a neurologist for many years. They wanted to assist the primary care physicians make earlier diagnoses to ensure the patients got the help they needed before significant neurological damage took place due to delays in diagnosis.
The Client Problem
• Patients not diagnosed and sent to a Neurologist until close to 10 years
• The patients were already in advanced stages of the condition by then
• Therefore the drug would be less effective as most of the damage had already occurred before the patients were given the drug.
• The client wished to assist the physicians make faster decision to refer the patient.
The Solution
Eularis examined anonymous patient record data and divided it into two groups for analysis. Eularis then utilized thousands of patient records to train our machine learning based algorithms to identify what it was about the patients that could allow them to be diagnosed far earlier definitely.
The Outcome
The client was able to create simple diagnostic tools for the Primary Care Physicians to use if a patient had the identified symptom cluster so that they could be reasonably sure that this was the diagnosis and refer the patient to a Specialist much faster.
Although the client is in early days of getting physicians into the program, the client has reported a 23% incremental increase, so far, in patients being put on their treatment in the zip codes where the system has been implemented with pilot Primary Care Physicians than before implementation of the system
To achieve these kinds of results, contact Eularis today.
Latest News
Read our latest news here.
We’re Doing AI” Is Not a Board Answer
There is a moment I have seen play out in pharmaceutical boardrooms again and again. It usually comes in the second half of the agenda,
Why Most AI Governance Frameworks Are the Wrong Fit for Pharma
Most pharmaceutical organizations now have some form of AI governance. On paper, that sounds reassuring. In practice, it often means a policy document, a review
Why Most Pharma AI Strategies Fail the CFO Test
Most pharmaceutical organizations do not struggle to explain what their AI programmes do. They struggle to explain, in financial terms, why those programmes deserve sustained